Table 4.

Median confluence increased overall for all lineages at therapeutic doses

Experience	Proliferation median (IQR) All lineages	P value compared to the control
Ozanimod control	28.6 (10.8)	–
Ozanimod 1.6 µM	63.5 (53.9)	< 0.001
Ponesimod control	38.7 (31.2)	–
Ponesimod 1.6 µM	85.7 (24.8)	< 0.001
Ponesimod 5.5 µM	81.9 (48.5)	< 0.001
Fingolimod control	45.6 (69.2)	–
Fingolimod 1.6 µM	67.1 (60.2)	0.094
Siponimod control	85.6 (67.6)	–
Siponimod 0.5 µM	81.5 (53.1)	0.71
Siponimod 1.6 µM	75.6 (43.3)	0.231